Literature DB >> 22941287

New insights into huperzine A for the treatment of Alzheimer's disease.

Hai-Yan Zhang1.   

Abstract

Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD). Accordingly, some new mechanisms of action for huperzine A have been discovered over the past decades. In addition to its AChE inhibitory effect, potent multifaceted neuroprotective effect through activating cholinergic system and directly acting on mitochondria have been explored. Moreover, in order to maximize the efficacy and safety of huperzine A therapy, great efforts have been made to optimize drug delivery system. In the present article, an attempt is made to discuss the current progress and future perspective for huperzine A therapy in AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941287      PMCID: PMC4003111          DOI: 10.1038/aps.2012.128

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  59 in total

Review 1.  The internal structure of mitochondria.

Authors:  T G Frey; C A Mannella
Journal:  Trends Biochem Sci       Date:  2000-07       Impact factor: 13.807

2.  Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury.

Authors:  X Q Xiao; R Wang; X C Tang
Journal:  J Neurosci Res       Date:  2000-09-01       Impact factor: 4.164

3.  Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death".

Authors:  Scott F Roberts; Martin A Fischhoff; Stacey A Sakowski; Eva L Feldman
Journal:  Acad Med       Date:  2012-03       Impact factor: 6.893

4.  Pharmacokinetics of huperzine A in dogs following single intravenous and oral administrations.

Authors:  Dafeng Chu; Wanhui Liu; Youxin Li; Pengfei Li; Jingkai Gu; Ke Liu
Journal:  Planta Med       Date:  2006-05       Impact factor: 3.352

5.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

6.  Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice.

Authors:  Zhi-fei Wang; Li-li Tang; Han Yan; Yu-jun Wang; Xi-can Tang
Journal:  Pharmacol Biochem Behav       Date:  2006-05-09       Impact factor: 3.533

7.  T33, a novel peroxisome proliferator-activated receptor γ/α agonist, exerts neuroprotective action via its anti-inflammatory activities.

Authors:  Ying Wang; Yu-she Yang; Xi-can Tang; Hai-yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-08-01       Impact factor: 6.150

8.  Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells.

Authors:  R Wang; X Q Xiao; X C Tang
Journal:  Neuroreport       Date:  2001-08-28       Impact factor: 1.837

9.  A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Authors:  M S Rafii; S Walsh; J T Little; K Behan; B Reynolds; C Ward; S Jin; R Thomas; P S Aisen
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

Review 10.  Pharmacologic modelling of Alzheimer's disease.

Authors:  T Sunderland; P N Tariot; H Weingartner; D L Murphy; P A Newhouse; E A Mueller; R M Cohen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1986       Impact factor: 5.067

View more
  11 in total

Review 1.  Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress.

Authors:  Mohammed Akbar; Musthafa Mohamed Essa; Ghazi Daradkeh; Mohamed A Abdelmegeed; Youngshim Choi; Lubna Mahmood; Byoung-Joon Song
Journal:  Brain Res       Date:  2016-02-13       Impact factor: 3.252

2.  Celebrating the 80th anniversary of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM).

Authors:  Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2012-09       Impact factor: 6.150

Review 3.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

4.  In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.

Authors:  Namrata Singh; Jana Hroudová; Zdeněk Fišar
Journal:  Mol Neurobiol       Date:  2016-09-23       Impact factor: 5.590

5.  Fraction n-Butanol of Radix Notoginseng Protects PC12 Cells from Aβ25-35-Induced Cytotoxicity and Alleviates Cognitive Deficits in SAMP8 Mice by Attenuating Oxidative Stress and Aβ Accumulation.

Authors:  Jin-Lan Huang; Ying-Qin Feng; Li-Ru Bai; Mei-Chun Qin; Zhe-Hao Xu; Zhao-Rong Liu; Wen-Bing Chen; Deng-Pan Wu; Zhen-Guo Zhong
Journal:  Evid Based Complement Alternat Med       Date:  2017-10-03       Impact factor: 2.629

6.  Huperzine A and Huperzine B Production by Prothallus Cultures of Huperzia selago (L.) Bernh. ex Schrank et Mart.

Authors:  Wojciech J Szypuła; Beata Wileńska; Aleksandra Misicka; Agnieszka Pietrosiuk
Journal:  Molecules       Date:  2020-07-17       Impact factor: 4.411

7.  Huperzine A lowers intraocular pressure via the M3 mAChR and provides retinal neuroprotection via the M1 mAChR: a promising agent for the treatment of glaucoma.

Authors:  Ping Yu; Wen-Pei Dong; Ya-Bin Tang; Hong-Zhuan Chen; Yong-Yao Cui; Xiao-Lan Bian
Journal:  Ann Transl Med       Date:  2021-02

Review 8.  Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.

Authors:  María Jesús Friedli; Nibaldo C Inestrosa
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

Review 9.  Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review.

Authors:  Sedigheh Eskandari; Soraya Sajadimajd; Loghman Alaei; Zhaleh Soheilikhah; Hossein Derakhshankhah; Gholamreza Bahrami
Journal:  Neurotox Res       Date:  2021-06-25       Impact factor: 3.911

10.  Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.

Authors:  Qingqing Meng; Aiping Wang; Hongchen Hua; Ying Jiang; Yiyun Wang; Hongjie Mu; Zimei Wu; Kaoxiang Sun
Journal:  Int J Nanomedicine       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.